novartis, poh and tpm voltaren, page-2

Yes turps. Interesting times ahead with diclofenac.
I can't see Novartis waiting too long after Themis launch to bring their product on the market.
It still interests me that Themis have also chosen to run with their own product, considering that they produce the product for Novartis.
It would seem that Themis don't want to miss an opportunity to grab a portion of the direct market. How they'll compete will be interesting.
Hopefully this means that there is a significant marketing push by both.
How Novartis markets it compared to its existing product will be fascinating, whether they use the 400% increased penetration and rapid absorption is crucial for the significance of TPM awareness.

My understanding is that the Themis product will be a low price point and looking for mass turn over in a country with 1 billion+ people.